

1.-5. (Canceled)

6. (Previously presented) The method of claim 7 wherein the cellular protease is calpain.

7. (Currently amended) A method of decreasing viral replication in cells, the method comprising decreasing levels of functional cellular protease in the cells by exposing the cells to a calpain inhibitor, wherein the viral replication is caused by a human cytomegalovirus, ~~a herpes simplex virus, or a varicellar zoster virus.~~

8. (Original) The method of claim 7 wherein the calpain inhibitor is E64D or Z-Leu-Leu-H.

9.-13. (Canceled)

14. (Previously presented) The method of claim 15 wherein the cellular protease is calpain.

15. (Currently Amended) A method of treating a viral infection in a subject, the method comprising administering to the subject an amount of a compound effective to decrease levels of functional cellular protease in cells of the subject wherein the viral infection is caused by a human cytomegalovirus, ~~a herpes simplex virus, or a varicellar zoster virus~~ and the compound is a calpain inhibitor.

16. (Original) The method of claim 15 wherein the calpain inhibitor is E64d or Z-Leu-Leu-H.

17.- 18. (Canceled)

Respectfully submitted,

January 31, 2005
Date

Karla M. Weyand
Karla M. Weyand
Registration No. 40,223

Rogalskyj & Weyand, LLP
P.O. Box 44
Livonia, New York 14487-0044
Tel: 716-626-5380
Fax: 716-626-5384

I hereby certify that this document is being deposited with the U.S. Postal Service as first class mail on 1/31/05 under 37 CFR 1.8 and is addressed to the Commissioner for Patent, PO Box 1450, Alexandria, VA 22313-1450

Karla M. Weyand
Signature of Person Mailing Correspondence

Karla M. Weyand
Typed Name of Person Mailing Correspondence